- Home
- CNTB vs HEQ Comparison
CNTB vs HEQ Comparison
Compare CNTB & HEQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CNTB | HEQ |
|---|---|---|
| Founded | 2012 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 140.4M | 139.0M |
| IPO Year | 2020 | 2010 |
Fundamental Metrics
Financial Performance| Metric | CNTB | HEQ |
|---|---|---|
| Price | $1.32 | $11.45 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $8.67 | N/A |
| AVG Volume (30 Days) | ★ 1.6M | 20.8K |
| Earning Date | 08-13-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $64,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.06 | $10.46 |
| 52 Week High | $3.82 | $12.00 |
Technical Indicators
Market Signals| Indicator | CNTB | HEQ |
|---|---|---|
| Relative Strength Index (RSI) | 32.54 | 43.41 |
| Support Level | N/A | $11.27 |
| Resistance Level | $2.78 | $11.63 |
| Average True Range (ATR) | 0.26 | 0.21 |
| MACD | -0.11 | -0.05 |
| Stochastic Oscillator | 11.45 | 34.14 |
Price Performance
Historical ComparisonAbout CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.
About HEQ John Hancock Hedged Equity & Income Fund of Beneficial Interest
John Hancock Hedged Equity & Income Fund is a closed-end management investment company. Its investment objective is to provide total return, with a focus on current income and gains, and to include long-term capital appreciation. It invests in various sectors such as financials, consumer discretionary, information technology, energy, healthcare, materials, real estate, consumer staples, short-term investments, and others.